NEW&EVENTS

Models May Help in Weighing Risks of Rituximab's Long-term Use in AAV 2021-02-23

New statistical models could help to predict the risk of relapse and infection following ongoing rituximab treatment in people with ANCA-associated vasculitis (AAV), a study suggests.These models may aid in clinical decisions about the relative risks and b..

Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis 2021-02-19

This article was originally published here Am J Health Syst Pharm. 2021 Feb 18:zxab042. doi: 10.1093/ajhp/zxab042. Online ahead of print. ABSTRACT DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is..

Secukinumab 'significantly' more effective in DMARD-naïve patients with PsA 2021-02-08

Secukinumab is effective in psoriatic arthritis at 6 and 12 months, with significantly better remission, low disease activity, retention and response rates in patients naïve to disease-modifying antirheumatic drugs, according to data.“The treatment optio..

Pritelivir Phase III clinical trials for HSV immunocompromised patients 2021-02-04

The medicine Pritelivir is to enter Phase III clinical trials for the treatment of immunocompromised patients who have acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections. Immunocompromised patients with HSV often have a chronic form of the..

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA) 2021-01-26

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial Background: Although targeted biological trea..

FDA Approves Subcutaneous Daratumumab Plus VCd for Newly Diagnosed Light-Chain Amyloidosis 2021-01-19

January 15, 2021 - The FDA has approved daratumumab and hyaluronidase-fihj, a subcutaneous formulation of daratumumab, for use in combination with bortezomib, cyclophosphamide, and dexamethasone in the treatment of patients with newly diagnosed light-chain amy..

FDA Grants Breakthrough Therapy Designation to Tiragolumab Plus Atezolizumab for PD-L1–High NSCLC 2021-01-12

January 5th, 2021 - The FDA has granted a breakthrough therapy designation to the anti-TIGIT therapy tiragolumab for use in combination with atezolizumab in the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors are PD-L1 ..

Sandoz Canada Gains Marketing Approval for Adalimumab Biosimilar 2021-01-05

The Sandoz adalimumab biosimilar Hyrimoz has been approved by Health Canada for the treatment of 9 rheumatologic and gastrointestinal conditions—in effect, all the indications as for the reference brand, Humira.Adalimumab is a fully human tumor necrosis f..

FDA Grants Priority Review to Pembrolizumab Plus Chemo for Advanced Esophageal or GEJ Cancer 2020-12-29

The FDA granted priority review to a new supplemental biologics license application for pembrolizumab (Keytruda) in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic esophageal and gastroeso..

首页上一页当前第7/9页共78条记录每页9条5 678 9 下一页尾页